SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (18794)4/7/1998 1:04:00 PM
From: bluejeans  Read Replies (2) | Respond to of 32384
 
Have you received any feedback from the Ligand presentation at the AIDS conference?

Bob



To: Henry Niman who wrote (18794)4/7/1998 2:56:00 PM
From: Mudcat  Read Replies (1) | Respond to of 32384
 
Henry per your comment:
The follow-up trial (Tamoxifen vs Evista) was set to begin almost immediately and interim data will come in just in time for the Targretin challenge (Targretin vs whoever wins the Tamoxifen/Evista match-up)

1. Why would the winner go against Targretin?
2. Is Targretin ready now? Why not have a 3 way challenge?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News